Natural History of Ocular GVHD

目前尚无关于该方案的数据可供报告。 迄今为止，已入组39例受试者，目前仍有31例积极入组（5例死亡，2例因难以返回NIH接受检查而退出，1例因总体医疗负担而选择退出）。23名参与者在自体干细胞移植后完成了至少1年的随访。 已建议大部分患者使用局部环孢素滴眼液以应对眼部指标的变化（症状、泪液分泌下降或表面干燥恶化）。对方案进行了修订，以纳入健康志愿者，以提供正常泪液样本，以增加我们的正常对照数据库，在2013年进行日期审查时，认为该数据库不充分。 我们的团队希望将患者症状和检查结果的变化与泪液生物标志物的变化相关联。 我们预计在下一个报告期内完成对大约25名参与者和一个类似规模的对照组的初步数据分析。

There are no data yet to report on this protocol. To date, 39 subjects have been enrolled, with 31 remaining actively enrolled at this time (5 lost to death, 2 withdrew due to difficulty traveling back to NIH for exams, and 1 elected to withdraw due to overall burden of medical care). 23 participants have completed at least 1 year of follow-up following autologous stem cell transplant. A significant portion of the patients have been advised to use topical cyclosporine eye drops in response to changes in ocular indicators (symptoms, drop in Schirmers tear production, or worsening of surface dryness). The protocol has been amended to include healthy volunteers to contribute normal tear fluid samples to augment our normal control data base, which was deemed inadequate at time of date review in 2013. Our team hopes to correlate changes in patient symptoms and exam findings with changes in the tear fluid biomarkers. We anticipate completing a preliminary data analysis of approximately 25 participants and a similarly sized control group by the next reporting period.